Pharma News
Sun Pharma looking to buy Sweden’s Meda
India-based Sun Pharmaceutical Industries (Sun Pharma) is reportedly in talks to acquire Swedish drugmaker Meda for US$5–6 billion.
Actavis makes definitive agreement with Warner Chilcott
US generic drugmaker Actavis (formerly Watson) and Irish drugmaker Warner Chilcott announced on 20 May 2013 that the two companies had entered into a definitive agreement under which Actavis will acquire Warner Chilcott in a stock-for-stock transaction valued at approximately US$8.5 billion.
Actavis in discussions to buy Warner Chilcott
US generics maker Actavis (formerly Watson) confirmed on 14 May 2013 that the company had entered into discussions to buy Irish drugmaker Warner Chilcott.
Valeant deal to acquire Actavis on hold
Drugmaker Valeant Pharmaceuticals International (Valeant) was in talks to acquire generics manufacturer Actavis for more than US$13 billion, in what would rank as one of the biggest healthcare deals this year. However, reports are that the deal is now on hold.
UK accuses GSK of delaying generics
The UK’s competition watchdog is accusing GlaxoSmithKline (GSK) of delaying the entry of generics to its antidepressant drug Seroxat (paroxetine) by paying rival companies to stay off the market.
Generics drugmakers should be held responsible for injuries
In the long saga of generics pre-emption, The New York Times is adding its opinion to the argument of whether generics makers are liable for injuries caused by their products. The newspaper believes that ‘manufacturers should bear responsibility for making sure their drugs are safe and effective’ and is urging US Congress to amend laws to allow patients to sue generics manufacturers.
Greece and Syria facing severe drug shortages
Greece and Syria are both facing severe shortages in essential medicines, but for very different reasons.
Drugmakers accused of stopping shipments to Greece
Greece is facing a severe drug shortage in more than 200 drugs. The worrying situation is being blamed on drugmakers that have stopped shipping their products to the country due to debts or fear of parallel trade.
Drug shortages linked to quality control costs
Lack of reward for manufacturing quality is forcing manufacturers of sterile injectable generics to reduce investments into quality system and is leading to drug shortages, according to FDA officials [1].
Sun Pharma ends attempt to gain full control of Taro
Sun Pharmaceutical Industries (Sun Pharma) announced on 8 February 2013 that it had given up on its effort to buy the remaining stock of Taro Pharmaceutical Industries (Taro) for about US$685 million after Taro shareholders held out for a higher price.
